

Judith R Kroep

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8459930/publications.pdf>

Version: 2024-02-01

157
papers

8,271
citations

41344

49
h-index

51608

86
g-index

159
all docs

159
docs citations

159
times ranked

12583
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of a Self-Monitoring Quality of Life Intervention in Outpatients with Breast Cancer: A Preliminary Report of A Randomized Controlled Trial. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 53-59.	1.2	0
2	Short-Term Fasting Synergizes with Solid Cancer Therapy by Boosting Antitumor Immunity. <i>Cancers</i> , 2022, 14, 1390.	3.7	8
3	Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IB Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2934-2945.	1.6	6
4	Discontinuation of adjuvant endocrine therapy and impact on quality of life and functional status in older patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 567-577.	2.5	10
5	Comparable effectiveness of 45- and 20-min post-infusion scalp cooling time in preventing paclitaxel-induced alopecia – a randomized controlled trial. <i>Supportive Care in Cancer</i> , 2022, , .	2.2	1
6	Symptoms of anxiety but not depression before start of taxane-based chemotherapy are associated with peripheral neuropathy: a multicenter study in women with breast cancer. <i>Supportive Care in Cancer</i> , 2022, 30, 6947-6953.	2.2	5
7	Psychosocial determinants of adherence with oral anticancer treatment: “we don’t need no education”. <i>Acta Oncologica</i> , 2021, 60, 87-95.	1.8	14
8	Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013-14) trial. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 741-758.	2.5	27
9	The variant T allele of PvuII in ESR1 gene is a prognostic marker in early breast cancer survival. <i>Scientific Reports</i> , 2021, 11, 3249.	3.3	5
10	Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 407.e1-407.e16.	1.3	11
11	The prognostic performance of PREDICT+ in patients (pts) with HER2-positive (HER2+) early-stage breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 524-524.	1.6	1
12	Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision making. <i>Gynecologic Oncology</i> , 2021, 161, 727-733.	1.4	2
13	The RAD51-FFPE Test; Calibration of a Functional Homologous Recombination Deficiency Test on Diagnostic Endometrial and Ovarian Tumor Blocks. <i>Cancers</i> , 2021, 13, 2994.	3.7	23
14	Tumor-stroma ratio is associated with Miller-Payne score and pathological response to neoadjuvant chemotherapy in HER2-negative early breast cancer. <i>International Journal of Cancer</i> , 2021, 149, 1181-1188.	5.1	24
15	Association of Chemotherapy Timing in Pregnancy With Congenital Malformation. <i>JAMA Network Open</i> , 2021, 4, e2113180.	5.9	27
16	Perceptions of Japanese and Dutch women with early breast cancer about monitoring their quality of life. <i>Journal of Psychosocial Oncology</i> , 2021, , 1-14.	1.2	0
17	Case series, Chemotherapy-induced cardiomyopathy: mind the family history!. <i>European Heart Journal - Case Reports</i> , 2021, 5, ytab333.	0.6	4
18	Quality of life and its associations with illness perceptions over a 3-month follow-up period in patients with non-small cell lung cancer: A prospective longitudinal study. <i>World Academy of Sciences Journal</i> , 2021, 3, .	0.6	0

#	ARTICLE	IF	CITATIONS
19	Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. <i>Breast</i> , 2021, 59, 327-338.	2.2	31
20	PROTECT: Prospective Phase-II-Trial Evaluating Adaptive Proton Therapy for Cervical Cancer to Reduce the Impact on Morbidity and the Immune System. <i>Cancers</i> , 2021, 13, 5179.	3.7	7
21	Development and validation of the PORTRET tool to predict recurrence, overall survival, and other-cause mortality in older patients with breast cancer in the Netherlands: a population-based study. <i>The Lancet Healthy Longevity</i> , 2021, 2, e704-e711.	4.6	14
22	Lifetime Transfusion Burden and Transfusion-Related Iron Overload in Adult Survivors of Solid Malignancies. <i>Oncologist</i> , 2020, 25, e341-e350.	3.7	5
23	Fertility-sparing surgery of cervical cancer >2 cm (International Federation of Gynecology and) <i>Tj ETQq1 1 0.784314 rgBT /Overlock</i> <i>Gynecological Cancer</i> , 2020, 30, 115-121.	2.5	27
24	Unraveling the Resistance of IGF-Pathway Inhibition in Ewing Sarcoma. <i>Cancers</i> , 2020, 12, 3568.	3.7	15
25	Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials. <i>Journal of Clinical Oncology</i> , 2020, 38, 3273-3281.	1.6	20
26	Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 680-689.	4.1	44
27	Metastatic breast cancer in older patients: A longitudinal assessment of geriatric outcomes. <i>Journal of Geriatric Oncology</i> , 2020, 11, 969-975.	1.0	11
28	Using a quality of life (QoL)-monitor: preliminary results of a randomized trial in Dutch patients with early breast cancer. <i>Quality of Life Research</i> , 2020, 29, 2961-2975.	3.1	5
29	Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial. <i>Nature Communications</i> , 2020, 11, 3083.	12.8	173
30	Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial. <i>British Journal of Cancer</i> , 2020, 122, 1453-1460.	6.4	22
31	Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 675-685.	2.5	4
32	Strong vaccine responses during chemotherapy are associated with prolonged cancer survival. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	83
33	<p><illness Perceptions and Quality of Life in Patients with Non-Small-Cell Lung Cancer: A 3-Month Follow-Up Pilot Study</p>. <i>Patient Related Outcome Measures</i> , 2020, Volume 11, 67-71.	1.2	6
34	High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes. <i>JAMA Oncology</i> , 2020, 6, 528.	7.1	17
35	PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 152, 102973.	4.4	31
36	The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas. <i>Cancers</i> , 2020, 12, 2805.	3.7	30

#	ARTICLE	IF	CITATIONS
37	Giving A Face to Chemotherapy-Induced Alopecia: A Feasibility Study on Drawings by Patients. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2020, 7, 218-224.	1.6	5
38	Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01). <i>Breast Cancer Research</i> , 2019, 21, 97.	5.0	6
39	Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1141-1147.	2.5	11
40	Efficacy and toxicity of chemoradiation with image-guided adaptive brachytherapy for locally advanced cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 257-265.	2.5	18
41	Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. <i>Gynecologic Oncology</i> , 2019, 154, 441-448.	1.4	74
42	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 1255-1268.	3.8	45
43	Effects of short-term fasting on cancer treatment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 209.	8.6	76
44	Adjuvant Zoledronic Acid in High-Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial. <i>Oncologist</i> , 2019, 24, 889-e421.	3.7	16
45	Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 862-876.	10.7	68
46	Higher ER load is not associated with better outcome in stage I-III breast cancer: a descriptive overview of quantitative HR analysis in operable breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 27-36.	2.5	10
47	Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 605-615.	2.5	13
48	Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study. <i>International Journal of Cancer</i> , 2019, 145, 1325-1333.	5.1	8
49	Validity and Reliability of the Japanese Version of the 10-Item Perceived Efficacy in Patient-Physician Interactions (PEPPI-10) Scale in Breast Cancer Outpatients. <i>Tohoku Journal of Experimental Medicine</i> , 2019, 249, 121-126.	1.2	2
50	Actively personalized vaccination trial for newly diagnosed glioblastoma. <i>Nature</i> , 2019, 565, 240-245.	27.8	637
51	Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure. <i>International Journal of Cancer</i> , 2019, 145, 274-283.	5.1	7
52	Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05). <i>Journal of the National Cancer Institute</i> , 2018, 110, 40-48.	6.3	138
53	Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer. <i>European Journal of Cancer</i> , 2018, 95, 59-67.	2.8	7
54	The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival. <i>Oncolimmunology</i> , 2018, 7, e1465166.	4.6	36

#	ARTICLE	IF	CITATIONS
55	Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 413-420.	2.5	5
56	The anti-tumor effect of RANKL inhibition in malignant solid tumors – A systematic review. <i>Cancer Treatment Reviews</i> , 2018, 62, 18-28.	7.7	103
57	Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe. <i>Cancer Treatment Reviews</i> , 2018, 62, 74-90.	7.7	61
58	ATIM-20. GAPVAC-101 TRIAL OF A HIGHLY PERSONALIZED PEPTIDE VACCINATION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi5-vi5.	1.2	0
59	Effects of controlled ovarian stimulation on toxicity of TAC chemotherapy in early breast cancer patients. <i>Cancer Management and Research</i> , 2018, Volume 10, 3931-3935.	1.9	2
60	Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 65-74.	2.5	11
61	Validation and Implementation of BRCA1/2 Variant Screening in Ovarian Tumor Tissue. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 600-611.	2.8	18
62	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. <i>Molecular and Cellular Proteomics</i> , 2018, 17, 2132-2145.	3.8	41
63	GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2000-2000.	1.6	17
64	Assessment and management of bone health in women treated with adjuvant anastrozole in the DATA study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 534-534.	1.6	0
65	Disclosing the Uncertainty Associated with Prognostic Estimates in Breast Cancer. <i>Medical Decision Making</i> , 2017, 37, 179-192.	2.4	39
66	Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	19
67	CDK4/6 inhibition in early and metastatic breast cancer: A review. <i>Cancer Treatment Reviews</i> , 2017, 60, 130-138.	7.7	49
68	Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1502-1511.	10.7	119
69	Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1211-1220.	10.7	45
70	Cross-cultural comparison of breast cancer patients' Quality of Life in the Netherlands and Japan. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 459-471.	2.5	26
71	Serum levels of IGF-1 and IGF-BP3 are associated with event-free survival in adult Ewing sarcoma patients treated with chemotherapy. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2963-2970.	2.0	12
72	Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTT0 Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1421-1429.	1.6	116

#	ARTICLE	IF	CITATIONS
73	Anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure.. Journal of Clinical Oncology, 2017, 35, 523-523.	1.6	1
74	Association of T cell responses after vaccination with HPV16 long peptides for late stage cervical cancer with prolonged survival.. Journal of Clinical Oncology, 2017, 35, 5525-5525.	1.6	6
75	Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer. Oncotarget, 2017, 8, 15610-15620.	1.8	21
76	Axillary staging in breast cancer patients treated with neoadjuvant chemotherapy in two Dutch phase III studies. Oncotarget, 2017, 8, 46557-46564.	1.8	6
77	A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial. Cancer, 2016, 122, 2961-2970.	4.1	7
78	Importance of patient reported outcome measures versus clinical outcomes for breast cancer patients evaluation on quality of care. Breast, 2016, 27, 62-68.	2.2	26
79	The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis. Breast Cancer Research and Treatment, 2016, 156, 361-370.	2.5	11
80	Use of implicit persuasion in decision making about adjuvant cancer treatment: A potential barrier to shared decision making. European Journal of Cancer, 2016, 66, 55-66.	2.8	53
81	Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses. Science Translational Medicine, 2016, 8, 334ra52.	12.4	164
82	Insulin-like growth factor 1 receptor expression and IGF1R 3129G>>T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01). Breast Cancer Research, 2016, 18, 3.	5.0	30
83	RE: Serum vit D levels and response to molecular subtypes in breast cancer. Breast, 2016, 27, 186.	2.2	0
84	Vitamin D (25-OH D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01). Breast, 2016, 25, 69-74.	2.2	29
85	The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study. BMC Cancer, 2015, 15, 652.	2.6	170
86	Breast cancer specialists'™ views on and use of risk prediction models in clinical practice: A mixed methods approach. Acta Oncologica, 2015, 54, 361-367.	1.8	24
87	Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: Current and future evidence. Cancer Treatment Reviews, 2015, 41, 271-276.	7.7	34
88	Disorganised stroma determined on pre-treatment breast cancer biopsies is associated with poor response to neoadjuvant chemotherapy: Results from the NEOZOTAC trial. Molecular Oncology, 2015, 9, 1120-1128.	4.6	28
89	Optical Mammography Using Diffuse Optical Spectroscopy for Monitoring Tumor Response to Neoadjuvant Chemotherapy in Women with Locally Advanced Breast Cancer. Clinical Cancer Research, 2015, 21, 577-584.	7.0	32
90	Early identification of non-responding locally advanced breast tumors receiving neoadjuvant chemotherapy. , 2015, ,		1

#	ARTICLE	IF	CITATIONS
91	We're in this together: Patients', caregivers' and health care providers' illness perceptions about non-small-cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2015, 90, 575-581.	2.0	7
92	Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 821-827.	4.1	49
93	Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. <i>Annals of Oncology</i> , 2015, 26, 1280-1291.	1.2	177
94	Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1271-1286.	4.2	161
95	Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01). <i>Breast Cancer Research and Treatment</i> , 2015, 149, 461-466.	2.5	16
96	A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon- γ in patients with recurrent epithelial ovarian cancer. <i>Annals of Oncology</i> , 2015, 26, 2141-2149.	1.2	144
97	Randomised study of tegafur-uracil plus leucovorin versus capecitabine as first-line therapy in elderly patients with advanced colorectal cancer - TLC study. <i>Journal of Geriatric Oncology</i> , 2015, 6, 307-315.	1.0	15
98	Illness Perceptions in Women with Breast Cancer - a Systematic Literature Review. <i>Current Breast Cancer Reports</i> , 2015, 7, 117-126.	1.0	53
99	Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1879-1887.	2.5	10
100	Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 247-252.	2.5	18
101	A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. <i>Oncotarget</i> , 2015, 6, 32228-32243.	1.8	58
102	The Clinical Approach Toward Giant Cell Tumor of Bone. <i>Oncologist</i> , 2014, 19, 550-561.	3.7	199
103	Adherence and patients' experiences with the use of oral anticancer agents. <i>Acta Oncologica</i> , 2014, 53, 259-267.	1.8	68
104	Improved survival of patients with cervical cancer treated with image-guided brachytherapy compared with conventional brachytherapy. <i>Gynecologic Oncology</i> , 2014, 135, 231-238.	1.4	200
105	Feasibility of tailored follow-up for patients with early breast cancer. <i>Breast</i> , 2014, 23, 852-858.	2.2	6
106	Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01). <i>Annals of Oncology</i> , 2014, 25, 998-1004.	1.2	33
107	Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer. <i>Onc Immunology</i> , 2014, 3, e962397.	4.6	27
108	In Reply. <i>Oncologist</i> , 2014, 19, 1208-1208.	3.7	0

#	ARTICLE	IF	CITATIONS
109	Validity of Adjuvant! Online program in older patients with breast cancer: a population-based study. <i>Lancet Oncology</i> , The, 2014, 15, 722-729.	10.7	81
110	Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2014, 40, 86-92.	7.7	52
111	Multicenter Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging (MALDI MSI) Identifies Proteomic Differences in Breast-Cancer-Associated Stroma. <i>Journal of Proteome Research</i> , 2014, 13, 4730-4738.	3.7	72
112	Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients â€” A phase II trial. <i>European Journal of Cancer</i> , 2014, 50, 2190-2200.	2.8	67
113	Primary Ewing sarcoma of the iris. <i>Lancet</i> , The, 2014, 383, 256.	13.7	2
114	The Need for Improvement of the Treatment of Advanced and Metastatic Cervical Cancer, the Rationale for Combined Chemo-Immunotherapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2014, 14, 190-203.	1.7	64
115	A multidisciplinary approach to giant cell tumors of tendon sheath and synoviumâ€”A critical appraisal of literature and treatment proposal. <i>Journal of Surgical Oncology</i> , 2013, 107, 433-445.	1.7	60
116	Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. <i>Lancet Oncology</i> , The, 2013, 14, 901-908.	10.7	487
117	Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854). <i>Breast Cancer Research and Treatment</i> , 2013, 139, 371-379.	2.5	127
118	Development of a Decision Aid about fertility preservation for women with breast cancer in the Netherlands. <i>Journal of Psychosomatic Obstetrics and Gynaecology</i> , 2013, 34, 170-178.	2.1	77
119	Chemotherapy Alters Monocyte Differentiation to Favor Generation of Cancer-Supporting M2 Macrophages in the Tumor Microenvironment. <i>Cancer Research</i> , 2013, 73, 2480-2492.	0.9	285
120	Reliability of core needle biopsy for determining ER and HER2 status in breast cancer. <i>Annals of Oncology</i> , 2013, 24, 931-937.	1.2	58
121	Quantitative assessment of lymph vascular space invasion (LVSI) provides important prognostic information in node-negative breast cancer. <i>Annals of Oncology</i> , 2013, 24, 2994-2998.	1.2	11
122	The prognostic role of TGF- β 2 signaling pathway in breast cancer patients. <i>Annals of Oncology</i> , 2013, 24, 384-390.	1.2	65
123	Illness Perceptions and Quality of Life in Japanese and Dutch Women with Breast Cancer. <i>Journal of Psychosocial Oncology</i> , 2013, 31, 83-102.	1.2	40
124	Can Zoledronic Acid be Beneficial for Promoting Tumor Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy?. <i>Journal of Clinical Medicine</i> , 2013, 2, 188-200.	2.4	3
125	NEOZOTAC: Efficacy results from a phase III randomized trial with neoadjuvant chemotherapy (TAC) with or without zoledronic acid for patients with HER2-negative large resectable or stage II or III breast cancer (BC)â€”A Dutch Breast Cancer Trialistsâ€™ Group (BOOG) study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1028-1028.	1.6	2
126	An open-label international multicentric phase II study of nilotinib in progressive pigmented villo-nodular synovitis (PVNS) not amenable to a conservative surgical treatment.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10516-10516.	1.6	8

#	ARTICLE	IF	CITATIONS
127	Plasma VEGF-a, angiopoietin-2 (ANG2) and soluble(s)TIE2 in patients (pts) with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X).. Journal of Clinical Oncology, 2013, 31, 1072-1072.	1.6	1
128	A combined EpCAM and MCAM circulating tumor cell (CTC) CellSearch enrichment to improve CTC capture rate in stage II/III breast cancer: A Dutch Breast Cancer Trialists' Group (BOOG) side study.. Journal of Clinical Oncology, 2013, 31, e22106-e22106.	1.6	1
129	The management of diffuse-type giant cell tumour (pigmented villonodular synovitis) and giant cell tumour of tendon sheath (nodular tenosynovitis). Journal of Bone and Joint Surgery: British Volume, 2012, 94-B, 882-888.	3.4	69
130	Editorial: Advances in Epithelial Ovarian Cancer Therapy. Current Pharmaceutical Design, 2012, 18, 3735-3740.	1.9	10
131	Interleukin-6/interleukin-6 Receptor Pathway as a New Therapy Target in Epithelial Ovarian Cancer. Current Pharmaceutical Design, 2012, 18, 3816-3827.	1.9	54
132	The Role of Bevacizumab in Advanced Epithelial Ovarian Cancer. Current Pharmaceutical Design, 2012, 18, 3775-3783.	1.9	12
133	Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach. Breast Cancer Research, 2012, 14, R93.	5.0	50
134	Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer, 2012, 118, 1649-1655.	4.1	222
135	Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?. European Journal of Cancer, 2011, 47, 2431-2445.	2.8	386
136	First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC Soft Tissue and Bone Sarcoma Group study. Annals of Oncology, 2011, 22, 207-214.	1.2	163
137	Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone. BMC Cancer, 2010, 10, 462.	2.6	119
138	Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer Treatment Reviews, 2010, 37, 422-30.	7.7	160
139	Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation. European Journal of Cancer, 2010, 46, 3016-3021.	2.8	74
140	Diflomotecan, a promising homocamptothecin for cancer therapy. Expert Opinion on Investigational Drugs, 2009, 18, 69-75.	4.1	26
141	Extra-abdominal subcutaneous metastasis of a gastrointestinal stromal tumor: report of a case and a review of the literature. Journal of Cutaneous Pathology, 2009, 36, 565-569.	1.3	19
142	Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukoencephalopathy syndrome. Annals of Oncology, 2007, 18, 1745-1747.	1.2	118
143	Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2006, 58, 509-516.	2.3	14
144	Clinical Activity of Gemcitabine as a Single Agent and in Combination. , 2006, , 253-288.		3

#	ARTICLE	IF	CITATIONS
145	No evidence of gemcitabine accumulation during weekly administration. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 843-849.	1.9	14
146	Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer. <i>Annals of Oncology</i> , 2004, 15, 484-488.	1.2	18
147	Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer. <i>Annals of Oncology</i> , 2004, 15, 230-235.	1.2	30
148	Quantitative Real Time PCR of Deoxycytidine Kinase mRNA by Light Cyclor PCR; in Relation to Enzyme Activity. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2004, 23, 1347-1350.	1.1	2
149	Quantitative real time PCR of deoxycytidine kinase mRNA by Light Cyclor PCR in relation to enzyme activity and gemcitabine sensitivity. <i>Cancer Letters</i> , 2004, 213, 173-179.	7.2	20
150	Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods. <i>Molecular Imaging and Biology</i> , 2003, 5, 337-346.	2.6	73
151	Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. <i>Molecular Cancer Therapeutics</i> , 2002, 1, 371-6.	4.1	145
152	Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines. <i>British Journal of Cancer</i> , 2000, 83, 1069-1076.	6.4	80
153	Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2000, 1474, 5-12.	2.4	54
154	Gemcitabine and cisplatin: A schedule finding study. <i>Annals of Oncology</i> , 1999, 10, 1503-1510.	1.2	64
155	Experimental drugs and drug combinations in pancreatic cancer. <i>Annals of Oncology</i> , 1999, 10, S234-S238.	1.2	22
156	Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors. <i>Annals of Oncology</i> , 1999, 10, 441-448.	1.2	81
157	Gemcitabine and Paclitaxel: Pharmacokinetic and Pharmacodynamic Interactions in Patients With Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 1999, 17, 2190-2190.	1.6	141